Related Experiment Videos
[Clinical evaluation of a new oral cephem, cefprozil in children]
H Meguro1, T Tajima, H Shiraishi
1Department of Pediatrics, School of Medicine, Teikyo University.
Insights
Cefprozil (CFPZ) is a safe and effective antibiotic for treating common childhood infections like strep throat and skin infections. It showed good results in children, with no adverse reactions reported in the study.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Antibiotic research
Background:
- Community-acquired infections are a significant concern in pediatric populations.
- Evaluating new antibiotic options for children is crucial for effective treatment.
- Cefprozil (CFPZ) is a cephalosporin antibiotic with potential applications in pediatric care.
Purpose of the Study:
- To assess the efficacy, safety, and pharmacokinetics of Cefprozil (CFPZ) in pediatric patients.
- To determine the effectiveness of CFPZ against common pediatric bacterial infections.
- To evaluate the safety profile and pharmacokinetic parameters of CFPZ in children.
Main Methods:
- Clinical evaluation of Cefprozil (CFPZ) in children with various infections.
- Assessment of treatment outcomes for streptococcal pharyngitis, respiratory tract infections, skin infections, and urinary tract infections.
- Pharmacokinetic analysis including Cmax and T 1/2 beta determination after premeal administration.
Main Results:
- Cefprozil (CFPZ) demonstrated efficacy against streptococcal pharyngitis, pneumococcal lower respiratory tract infections, staphylococcal skin infections, and E. coli urinary tract infections.
- Lower efficacy was observed for lower respiratory tract infections and otitis media caused by Haemophilus influenzae.
- No adverse reactions were reported in 46 children treated with CFPZ.
- Pharmacokinetic parameters included a Cmax of approximately 3.2 mcg/ml and a T 1/2 beta of 1.4 hours with a 7.5 mg/kg premeal dose.
Conclusions:
- Cefprozil (CFPZ) is a safe and effective option for treating various community-acquired infections in children.
- The antibiotic shows promise for pediatric infectious disease management.
- Further investigation may be warranted for specific pathogens like Haemophilus influenzae.
Abstract:
Cefprozil (CFPZ, BMY-28100) was evaluated for its efficacy, safety and pharmacokinetics in children. CFPZ was effective against streptococcal pharyngitis, pneumococcal lower respiratory tract infections, staphylococcal skin infections and Escherichia coli urinary tract infections, but was less effective against lower respiratory tract infections and otitis media due to Haemophilus influenzae. No adverse reactions were encountered in 46 cases treated with CFPZ. With a premeal administration of 7.5 mg/kg, the Cmax was approximately 3.2 micrograms/ml and the T 1/2 beta was 1.4 hours. From the present study, CFPZ appears to be safe and effective against community-acquired childhood infections.